Mariam Murtazashvili will Head the Quality Department of the Company Biochimpharm

The modern world is especially full of challenges in the fields of science and technology. Georgian biopharmaceutical company "Biochimpharm", which has been on the market for decades, encourages innovation and is constantly evolving in a competitive environment.

This is confirmed by the fact that the company has won numerous local and international awards for the introduction of innovations and the development of healthy technologies. It should be noted that "Biochimpharm" is the only company in Georgia that has succeeded in the European mega-competition Horizon 2020 in terms of innovation and deserved a recommendation from the European Commission, as well as a certificate of excellence.

Mariam Murtazashvili, the new director of quality management, will help Biochimpharm to cope with the challenges and achieve the set goals. She received her higher education at Tbilisi State Medical University and is currently preparing for her PhD in Pharmacy. Mariam is ready to use her knowledge and experience to develop the company.

''The world is facing a growing problem such as antibiotic resistance. Today, phage preparations are the only available alternative to antibiotics. The main mission of Biochimpharm is to eliminate the irrational use of antibiotics and to defeat the global problem, antibiotic resistance. For this we use bacteriophage technology and create natural, safe and effective preparations. Quality management is a very sensitive and difficult position, but I accepted because I wanted to be a part of such a world-class business as the creation of phage preparations,''said Mariam Murtazashvili at Forbes Woman. 

Since 2018, Biochimpharm has been actively working on the introduction of the EU GMP (European / International Pharmaceutical Production Standard) standard in the enterprise. To date, the company has gone through certain stages, such as making plans for compliance with international standards and further implementation, attracting financial and intellectual resources, purchasing unique high-tech infrastructure systems and production lines throughout the region, etc. The enterprise is currently in the process of renovation and rearmament. They try not to fall behind the pre-written plan and want to start delivering phage produced by the EU-recognized GMP standard to their customers during 2022.

''We want to expand production. In particular, we want to develop new pharmaceutical forms of bacteriophage, as well as create new therapies for the treatment and prevention of various infections caused by resistant bacteria.

In general, our goal is to put the company and Georgia on the world biotechnology map and eliminate antibiotic resistance as one of the greatest threats to humanity,''said Mariam Murtazashvili.